At a glance
ClinicalIndex Comparison Record- ✓Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite by revised El Escorial criteria
- ✓Age 18 years or older
- ✓Time since onset of weakness ≤24 months at screening
- ✓Vital Capacity ≥50% of predicted measured by SVC or FVC
- ✕Clinically significant unstable medical condition other than ALS posing risk (e.g., cardiovascular instability, systemic infection)
- ✕Clinically significant abnormal liver or kidney function: ALT or AST >3× ULN or eGFR <30 mL/min/1.73m2
- ✕Unstable psychiatric disease, cognitive impairment, dementia, or substance abuse impairing informed consent
- ✕Active cancer or cancer history except treated skin cancers, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated with ≥3 years disease-free
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial
In Brief
A Phase 3 clinical trial evaluating Zilucoplan, Verdiperstat, and 6 other interventions for Amyotrophic Lateral Sclerosis. Currently recruiting, targeting 1,500 participants across 81 sites.
Signals
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Study Details
Timeline
Interventions
Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight
Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily
Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily
Drug: Pridopidine Administration: Oral Dose: 45mg twice daily
Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly
Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2
Drug: DNL343 Administration: Oral Dose: Once per day
Drug: NUZ-001. Administration: Oral. Dose: Once per day.